PD-176252
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525902

CAS#: 204067-01-6

Description: PD-176252 is a non-peptide gastrin-releasing peptide receptor (GRP-R, BB2) and neuromedin B receptor (NMB-R, BB1) antagonist (Ki values are 0.17 and 1.0 nM for BB1 and BB2 respectively). It inhibits proliferation of rat C6 glioma cells (IC50 = 2 μM) and inhibits NCI-H1299 xenograft proliferation in nude mice (IC50 = 5 μM).


Chemical Structure

img
PD-176252
CAS# 204067-01-6

Theoretical Analysis

MedKoo Cat#: 525902
Name: PD-176252
CAS#: 204067-01-6
Chemical Formula: C32H36N6O5
Exact Mass: 584.27
Molecular Weight: 584.677
Elemental Analysis: C, 65.74; H, 6.21; N, 14.37; O, 13.68

Price and Availability

Size Price Availability Quantity
10mg USD 400
Bulk inquiry

Synonym: PD-176252; PD 176252; PD176252.

IUPAC/Chemical Name: 1H-Indole-3-propanamide, N-((1-(5-methoxy-2-pyridinyl)cyclohexyl)methyl)-alpha-methyl-alpha-((((4-nitrophenyl)amino)carbonyl)amino)-, (alphaS)-

InChi Key: NNFUWNLENRUDHR-HKBQPEDESA-N

InChi Code: InChI=1S/C32H36N6O5/c1-31(18-22-19-33-27-9-5-4-8-26(22)27,37-30(40)36-23-10-12-24(13-11-23)38(41)42)29(39)35-21-32(16-6-3-7-17-32)28-15-14-25(43-2)20-34-28/h4-5,8-15,19-20,33H,3,6-7,16-18,21H2,1-2H3,(H,35,39)(H2,36,37,40)/t31-/m0/s1

SMILES Code: O=C(NCC1(C2=NC=C(OC)C=C2)CCCCC1)[C@](NC(NC3=CC=C([N+]([O-])=O)C=C3)=O)(C)CC4=CNC5=C4C=CC=C5

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Biological target: PD176252 is a potent antagonist of neuromedin-B preferring (BB1) and gastrin-releasing peptide-preferring (BB2) receptor with Kis of 0.17 nM and 1 nM for human BB1 and BB2 receptors, and 0.66 nM, 16 nM for Rat BB1 and BB2 receptors.
In vitro activity: This paper describes the development of a novel series of non-peptide, "balanced" neuromedin-B preferring (BB1)/gastrin-releasing peptide preferring (BB2) receptor ligands as exemplified by PD 176252. PD 176252, which exhibits nanomolar affinity for both the BB1 (Ki = 0.15 nM) and BB2 (Ki = 1.0 nM) receptors, has been demonstrated to be a competitive antagonist at these bombesin receptor subtypes. Reference: Bioorg Med Chem Lett. 1998 Sep 22;8(18):2589-94. https://pubmed.ncbi.nlm.nih.gov/9873586/
In vivo activity: The effects of PD 176252 [3-(1H-indol-3-yl)-N-[1-(5-methoxy-pyridin-2-yl)-cyclohexylmethyl]-2-methyl-2-[3-(nitro-phenyl)ureido]propionamide], a nonpeptide bombesin (BB) BB1/BB2 receptor antagonist, were assessed in rats using several ethologically relevant tests of anxiety. When administered directly to the dorsal raphé nucleus (DRN), PD 176252 (20-500 ng) increased social interaction under aversive conditions, as did the 5-HT1A receptor agonist 8-hydroxy-2(di-n-propylamino)tetralin (50 ng). Furthermore, intra-DRN microinfusion of the peptide antagonist (PD 176252) suppressed, whereas its agonist [neuromedin B (NMB)-30] promoted, the in vivo release of 5-HT in the ventral hippocampus. Reference: J Neurosci. 2006 Oct 11;26(41):10387-96. https://pubmed.ncbi.nlm.nih.gov/17035523/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 86.7 148.35

Preparing Stock Solutions

The following data is based on the product molecular weight 584.68 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Moody TW, Leyton J, Garcia-Marin L, Jensen RT. Nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells. Eur J Pharmacol. 2003 Aug 1;474(1):21-9. doi: 10.1016/s0014-2999(03)01996-4. PMID: 12909192. 2. Ashwood V, Brownhill V, Higginbottom M, Horwell DC, Hughes J, Lewthwaite RA, McKnight AT, Pinnock RD, Pritchard MC, Suman-Chauhan N, Webb C, Williams SC. PD 176252--the first high affinity non-peptide gastrin-releasing peptide (BB2) receptor antagonist. Bioorg Med Chem Lett. 1998 Sep 22;8(18):2589-94. doi: 10.1016/s0960-894x(98)00462-4. PMID: 9873586. 3. Merali Z, Bédard T, Andrews N, Davis B, McKnight AT, Gonzalez MI, Pritchard M, Kent P, Anisman H. Bombesin receptors as a novel anti-anxiety therapeutic target: BB1 receptor actions on anxiety through alterations of serotonin activity. J Neurosci. 2006 Oct 11;26(41):10387-96. doi: 10.1523/JNEUROSCI.1219-06.2006. PMID: 17035523; PMCID: PMC6674684.
In vitro protocol: 1. Moody TW, Leyton J, Garcia-Marin L, Jensen RT. Nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells. Eur J Pharmacol. 2003 Aug 1;474(1):21-9. doi: 10.1016/s0014-2999(03)01996-4. PMID: 12909192. 2. Ashwood V, Brownhill V, Higginbottom M, Horwell DC, Hughes J, Lewthwaite RA, McKnight AT, Pinnock RD, Pritchard MC, Suman-Chauhan N, Webb C, Williams SC. PD 176252--the first high affinity non-peptide gastrin-releasing peptide (BB2) receptor antagonist. Bioorg Med Chem Lett. 1998 Sep 22;8(18):2589-94. doi: 10.1016/s0960-894x(98)00462-4. PMID: 9873586.
In vivo protocol: 1. Merali Z, Bédard T, Andrews N, Davis B, McKnight AT, Gonzalez MI, Pritchard M, Kent P, Anisman H. Bombesin receptors as a novel anti-anxiety therapeutic target: BB1 receptor actions on anxiety through alterations of serotonin activity. J Neurosci. 2006 Oct 11;26(41):10387-96. doi: 10.1523/JNEUROSCI.1219-06.2006. PMID: 17035523; PMCID: PMC6674684. 2. Moody TW, Leyton J, Garcia-Marin L, Jensen RT. Nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells. Eur J Pharmacol. 2003 Aug 1;474(1):21-9. doi: 10.1016/s0014-2999(03)01996-4. PMID: 12909192.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Pereira PJ, Machado GD, Danesi GM, Canevese FF, Reddy VB, Pereira TC, Bogo MR, Cheng YC, Laedermann C, Talbot S, Lerner EA, Campos MM. GRPR/PI3Kγ: Partners in Central Transmission of Itch. J Neurosci. 2015 Dec 9;35(49):16272-81. doi: 10.1523/JNEUROSCI.2310-15.2015. PubMed PMID: 26658875; PubMed Central PMCID: PMC4682789.

2: Schepetkin IA, Kirpotina LN, Khlebnikov AI, Leopoldo M, Lucente E, Lacivita E, De Giorgio P, Quinn MT. 3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2. Biochem Pharmacol. 2013 Feb 1;85(3):404-16. doi: 10.1016/j.bcp.2012.11.015. Epub 2012 Dec 3. PubMed PMID: 23219934; PubMed Central PMCID: PMC3553303.

3: Tattersall M, Cordeaux Y, Charnock-Jones DS, Smith GC. Expression of gastrin-releasing peptide is increased by prolonged stretch of human myometrium, and antagonists of its receptor inhibit contractility. J Physiol. 2012 May 1;590(9):2081-93. doi: 10.1113/jphysiol.2012.228239. Epub 2012 Mar 12. PubMed PMID: 22411014; PubMed Central PMCID: PMC3447152.

4: Schepetkin IA, Kirpotina LN, Khlebnikov AI, Jutila MA, Quinn MT. Gastrin-releasing peptide/neuromedin B receptor antagonists PD176252, PD168368, and related analogs are potent agonists of human formyl-peptide receptors. Mol Pharmacol. 2011 Jan;79(1):77-90. doi: 10.1124/mol.110.068288. Epub 2010 Oct 13. PubMed PMID: 20943772; PubMed Central PMCID: PMC3014281.

5: Li X, Lv Y, Yuan A, Yi S, Ma Y, Li Z. Gastrin-releasing peptide promotes the growth of HepG2 cells via EGFR-independent ERK1/2 activation. Oncol Rep. 2010 Aug;24(2):441-8. PubMed PMID: 20596631.

6: Zhang Q, Bhola NE, Lui VW, Siwak DR, Thomas SM, Gubish CT, Siegfried JM, Mills GB, Shin D, Grandis JR. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol Cancer Ther. 2007 Apr;6(4):1414-24. PubMed PMID: 17431120.

7: Bédard T, Mountney C, Kent P, Anisman H, Merali Z. Role of gastrin-releasing peptide and neuromedin B in anxiety and fear-related behavior. Behav Brain Res. 2007 Apr 16;179(1):133-40. Epub 2007 Jan 31. PubMed PMID: 17335915.

8: Merali Z, Bédard T, Andrews N, Davis B, McKnight AT, Gonzalez MI, Pritchard M, Kent P, Anisman H. Bombesin receptors as a novel anti-anxiety therapeutic target: BB1 receptor actions on anxiety through alterations of serotonin activity. J Neurosci. 2006 Oct 11;26(41):10387-96. PubMed PMID: 17035523.

9: Moody TW, Nakagawa T, Kang Y, Jakowlew S, Chan D, Jensen RT. Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation. J Mol Neurosci. 2006;28(3):231-8. PubMed PMID: 16691010.

10: Moody TW, Leyton J, Garcia-Marin L, Jensen RT. Nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells. Eur J Pharmacol. 2003 Aug 1;474(1):21-9. PubMed PMID: 12909192.

11: Moody TW, Jensen RT, Garcia L, Leyton J. Nonpeptide neuromedin B receptor antagonists inhibit the proliferation of C6 cells. Eur J Pharmacol. 2000 Dec 8;409(2):133-42. PubMed PMID: 11104826.

12: Ashwood V, Brownhill V, Higginbottom M, Horwell DC, Hughes J, Lewthwaite RA, McKnight AT, Pinnock RD, Pritchard MC, Suman-Chauhan N, Webb C, Williams SC. PD 176252--the first high affinity non-peptide gastrin-releasing peptide (BB2) receptor antagonist. Bioorg Med Chem Lett. 1998 Sep 22;8(18):2589-94. PubMed PMID: 9873586.